This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Treatment landscape
Development of new classes of drugs* continue to reshape myeloma treatment landscape
- Increase in the number of treatment options has translated to improved survival over the last two decades
*This is not an exhaustive list.
ASCT, autologous stem cell transplant; BCMA, B-cell maturation antigen; MM, multiple myeloma; PI, proteasome inhibitor.
1. Kumar, et al. Blood. 2008;111:2516-2520. 2. Bhatnagar V, et al. Oncologist. 2017;22(11):1347-1353. 3. Baines AC, et al. Clin Cancer Res. 2022;28 (21): 4629–4633. 4. Labanca C, et al. Eur J Haematol. 2025;114(3):386-399.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.